Detalles de la búsqueda
1.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34671975
2.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34036560
3.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 107(3): 774-775, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35229573
4.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 106(4): 1182-1187, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586908
5.
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Haematologica
; 101(7): 872-8, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27081177
6.
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Cancer
; 121(13): 2185-92, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25809731
7.
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
Haematologica
; 100(8): 1096-102, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25911554
8.
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Haematologica
; 100(10): 1327-33, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26250580
9.
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Haematologica
; 100(10): 1334-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160879
10.
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Blood
; 119(3): 687-91, 2012 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-22128143
11.
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Blood
; 120(8): 1589-96, 2012 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22791289
12.
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Eur J Haematol
; 92(3): 181-8, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24330023
13.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(11): 1055-1066, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007748
14.
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant.
Cancers (Basel)
; 16(2)2024 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38254867
15.
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Biol Blood Marrow Transplant
; 19(1): 69-74, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22897964
16.
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Br J Haematol
; 163(5): 581-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24117042
17.
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Am J Pathol
; 181(5): 1870-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22974582
18.
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
Blood
; 118(3): 529-34, 2011 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482708
19.
Lupus anticoagulant hypoprothrombinemia syndrome: A case report.
Clin Case Rep
; 11(4): e7071, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37038533
20.
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
Cancers (Basel)
; 15(11)2023 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37296925